Holen Sie sich die Stockscreener-App
10.96
12.39%
-1.55
Handel nachbörslich:
10.97
0.010
+0.09%
Schlusskurs vom Vortag:
$12.51
Offen:
$12.7
24-Stunden-Volumen:
169.44K
Relative Volume:
1.03
Marktkapitalisierung:
$98.29M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-39.72M
KGV:
-0.5971
EPS:
-18.3554
Netto-Cashflow:
$-28.18M
1W Leistung:
-14.91%
1M Leistung:
-53.16%
6M Leistung:
-20.12%
1J Leistung:
-28.58%
1-Tages-Spanne:
$10.56
$13.13
1-Wochen-Bereich:
$10.56
$13.99
52-Wochen-Spanne:
$6.27
$39.75
Promis Neurosciences Inc Stock (PMN) Company Profile
Firmenname
Promis Neurosciences Inc
Sektor
Branche
Telefon
416-847-6898
Adresse
SUITE 200, 1920 YONGE STREET, TORONTO
Compare PMN vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PMN
Promis Neurosciences Inc
|
10.96 | 112.19M | 0 | -39.72M | -28.18M | -18.36 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Promis Neurosciences Inc Aktie (PMN) Neueste Nachrichten
Promis Neurosciences (NASDAQ:PMN) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
PMN Technical Analysis & Stock Price Forecast - Intellectia AI
Weekly Earnings: Will ProMIS Neurosciences Inc stock go up in YEARShare Buyback & Low Drawdown Investment Strategies - baoquankhu1.vn
Aug Volume: How does ProMIS Neurosciences Inc perform in inflationary periods2026 Sentiment & Risk Controlled Swing Alerts - baoquankhu1.vn
ProMIS Neurosciences Inc expected to post a loss of $1.91 a shareEarnings Preview - TradingView
[EFFECT] ProMIS Neurosciences Inc. SEC Filing - Stock Titan
Aug Mood: How cyclical is ProMIS Neurosciences Incs revenue stream2026 Institutional Moves & Low Risk Profit Maximizing Plans - baoquankhu1.vn
ProMIS Neurosciences 2025 Annual Report: Pipeline, Risks, and Strategic Objectives for Alzheimer’s Drug Development - Minichart
ProMIS Neurosciences (PMN) files $50M at-the-market sales supplement - Stock Titan
ProMIS Neurosciences 10-K: $0 Revenue, ($22.61) EPS, Net Loss $39.72M - TradingView
Alzheimer’s antibody lead and ALS programs at ProMIS (NASDAQ: PMN) - Stock Titan
ProMIS Neurosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
ProMIS Neurosciences reports $39.7M net loss for FY2025, cash $6.1M; raises $75.5M in Feb 2026 - TradingView
Heavy 2025 loss but big AD bet for ProMIS Neurosciences (PMN) with $175M funding - Stock Titan
ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights - ChartMill
Promis Neurosciences (PMN) to Release Earnings on Monday - Defense World
How does ProMIS Neurosciences Inc perform in inflationary periods2026 Technicals & Reliable Price Breakout Alerts - baoquankhu1.vn
If You Invested $1,000 in Promis Neuroscie (PMN) - stocktitan.net
Activity Recap: How cyclical is ProMIS Neurosciences Incs revenue streamDollar Strength & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
ProMIS Neurosciences (PMN) registers 13.83M shares after $75.5M private placement - Stock Titan
Wellington holds 9.99% of ProMIS Neurosciences (NASDAQ: PMN) via shares and warrants - Stock Titan
ProMIS Neurosciences to Present Data on ALS & Parkinsons - GlobeNewswire
ProMIS Neurosciences, Inc. (PMN) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Abg V Siv X Ltd Net Worth (2026) - GuruFocus
Abg V Siv Ix Ltd Net Worth (2026) - GuruFocus
Sentiment Recap: Can ProMIS Neurosciences Inc. continue delivering strong returns2026 Earnings Impact & Weekly Chart Analysis and Guides - baoquankhu1.vn
Promis Neurosciences (NASDAQ:PMN) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Promis Neurosciences (NASDAQ:PMN) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Published on: 2026-03-10 05:13:34 - baoquankhu1.vn
PMN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Trade Report: Can ProMIS Neurosciences Inc continue delivering strong returnsJuly 2025 Fed Impact & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Eugene Williams Increases Stake in ProMIS Neurosciences Inc with Recent Share Purchase - GuruFocus
ProMIS Neurosciences (PMN) director purchases 2,000 common shares in open market - Stock Titan
Published on: 2026-03-05 21:52:27 - baoquankhu1.vn
Eugene Williams Increases Stake in ProMIS Neurosciences Inc - GuruFocus
Promis Neurosciences (NASDAQ:PMN) Director Eugene Williams Buys 2,000 Shares - MarketBeat
Eugene Williams Acquires 1,000 Shares of Promis Neurosciences (NASDAQ:PMN) Stock - MarketBeat
ProMIS Neurosciences, Inc. (PMN.TO) Competitors - Meyka
PMN Stock Price and Chart — NASDAQ:PMN - TradingView
ProMIS Neurosciences : PMN - 24/7 Wall St.
Ally Bridge entities disclose ProMIS (PMN) shares and warrant terms - Stock Titan
PMN PE Ratio & Valuation, Is PMN Overvalued - Intellectia AI
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Can ADMA Biologics Inc deliver consistent EPS growthJuly 2025 Breakouts & Short-Term Trading Alerts - baoquankhu1.vn
Insider Buying: Johanne Kaplan Acquires Shares of ProMIS Neurosc - GuruFocus
Insider buy: ProMIS Neurosciences (PMN) CDO acquires 1,629 shares at $15.35 - Stock Titan
Final Results - ADVFN
What to expect from Gossamer Bio’s late-stage lung disease study - statnews.com
ProMIS Neurosciences CEO touts “watershed year” as PMN310 Alzheimer’s Phase 1b data nears - Defense World
Is ProMIS Neurosciences Inc. stock positioned well for digital economyWeekly Trend Recap & Smart Swing Trading Techniques - mfd.ru
Promis Neurosciences (NASDAQ:PMN) Cut to “Strong Sell” at Wall Street Zen - Defense World
Finanzdaten der Promis Neurosciences Inc-Aktie (PMN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):